OBJECTIVES: Despite the existence of standardized medical criteria, clinical diagnosis of Alzheimer’s disease remains difficult. Lack of diagnostic certainty or possible distress related to positive results could limit application of new testing technologies. Independent of the therapeutic value of prevention or cure, however, diagnostic information could have value in informing contingency planning or have intrinsic value: the value of “just knowing”. This paper aims to quantify respondents’ preferences for obtaining AD diagnostic tests and to estimate the perceived value of AD test information. METHODS: Discrete-choice experiment (DCE) and contingent-valuation (CV) questions were administered to N=1301 respondents aged 60 years or older in Germany and the United Kingdom. 12 pairs of virtual AD diagnostic tests were presented (defined by test type, test precision defined by false-positive or false-negative test results, and test cost) and a no-test alternative. DCE questions were based on a predetermined experimental design. A double-bounded, dichotomous-choice CV question was used to further elicit willingness to take an AD test and pay for it. Choice data of respondents interested in taking a test were analyzed using random-parameters logit. A probit model characterized respondents who were not willing to take a test. RESULTS: Most respondents in both countries had a positive value for AD diagnostic test information. Most respondents who indicated an interest in testing in Germany (N=631) and the UK (N=670) preferred brain imaging without radioactive marker, followed by brain imaging with radioactive marker and then spinal tap. Diagnostic tests with better precision were preferred. German respondents had relatively greater heterogeneous preferences and lower money-equivalent values for test features compared to UK respondents. CONCLUSIONS: Respondents preferred less invasive diagnostic procedures and tests with higher accuracy. Diagnostic test accuracy was more important than test type. Respondents expressed a willingness to pay up to €700 to receive a less invasive test with the highest accuracy.